top of page
gradientForSurfBreak.png

Item List

EIN News
xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

xCures, Inc., a clinical study platform provider, and Oblato, Inc., a biotechnology company, are pleased to announce the availability of OKN-007 through an intermediate size expanded access program (iEAP) for eligible patients with pediatric diffuse midline glioma (DMG), inclusive of diffuse intrinsic pontine glioma (DIPG). Oblato is currently developing OKN-007 as a treatment for glioblastoma multiforme (GBM).

Recent Posts

General News

Carlsmed.png

Hospitals Work Through Fallout from CrowdStrike Outage ...

Modern Healthcare

General News

Carlsmed.png

Humana Makes Investment in AI-powered Medicare Enrollment Platform Healthpilot ...

Fierce Healthcare

General News

Carlsmed.png

Healthcare Costs Set to Rise by as Much as 8% in 2025: PwC ...

Fierce Healthcare

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page